Navigation Links
New Data on Cimzia® (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease
Date:10/31/2011

ct, most commonly at the end of the small intestine (the ileum) and beginning of the large intestine (the colon).   If not effectively treated, it may result in the need for surgery and hospitalization. Crohn's disease has been estimated to affect as many as half a million Americans.  People with Crohn's can experience an ongoing cycle of flare-up and remission throughout their lives.

About Cimzia

Certolizumab pegol is the only PEGylated anti-TNF (Tumor Necrosis Factor).  It has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha.  Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation.  This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases.  The U.S. Food and Drug Administration (FDA) has approved certolizumab pegol for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have had an inadequate response to conventional therapy.  It is also approved for the treatment of adults with moderately to severely active rheumatoid arthritis.  Certolizumab pegol was approved in Switzerland for induction of a clinical response and for the maintenance of a clinical response and remission in patients with active Crohn's disease who have not responded adequately to conventional treatment in September 2007.

Please visit www.cimzia.com for full prescribing information for CIMZIA®.

Important Safety Information

Risk of Serious Infections and Malignancy

Patients treated with CIMZIA are at an increased risk for developing serious infections that may lead to hospitalization or death.  Most patients who developed these infections we
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
2. Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
3. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
4. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
5. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
6. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
7. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
8. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
9. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
10. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
11. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014  Quest Diagnostics (NYSE: DGX ), ... announced that its Board of Directors has elected Jeffrey ... December 1, 2014. Including Dr. Leiden, the Board has ... President and CEO of Vertex Pharmaceuticals.   Dr. Leiden ... experience in the pharmaceutical and biotechnology industries as well ...
(Date:10/22/2014)... 2014  Charlene Vernak, RPh, of Vernak Farms Pharmacy ... was awarded the George Roentsch Scholarship by the Professional ... in Houston during PCCA,s International ... annually to an independent pharmacist and PCCA member who ... Roentsch , a well-known pharmacist in the compounding community. ...
(Date:10/22/2014)... 22, 2014  Paper Pak Industries, a manufacturer ... ® Body Guard Bio, a disposable, highly ... bacteria and virus while protecting service providers and ... features a rugged, external nylon shell, watertight zipper, ... leak-proof inner chamber that contains contaminated and potentially ...
Breaking Medicine Technology:Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2
... Oct. 13 ConvaTec, a world-leading developer and marketer ... today announced that its top executives have been asked ... , the premier medical technology conference for CEOs, business ... the world. Well known for innovative ...
... AKRX ) will host a conference call on Tuesday, ... by a Q&A session.  The company will release earnings the ... Third Quarter 2010 Conference CallDate/Time: , Tuesday, November 2, ... 215-6895International Callers: , (913) 312-0860Confirmation Code: , ...
Cached Medicine Technology:ConvaTec to Present at AdvaMed 2010: The MedTech Conference 2
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter , ... add weight and length may be showing a genetic propensity ... adults, certain genes have been linked to increased body fat, ... fat and lean muscle, the researchers said. At 1 ... By ages 2 and 3, however, these genes were linked ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... of conventional in vitro fertilization (IVF) -- the incubation of ... in a device inside the vagina, new research suggests. ... device, called an INVOcell, might sharply cut costs for pricey ... technology more accessible to those who don,t live near big-city ...
(Date:10/20/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... is the must-have source of thousands of facts, figures ... 72 countries and 68 medical sector forecast categories the ... you with global, regional and national views on the ... future outlook. , The report gives you data for ...
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... City based non-profit organization that helps New Yorkers ... lasting, positive changes toward health, housing, recovery and ... who have transformed the local community through their ... Managing Director, Marc Shapses , has been ...
(Date:10/20/2014)... 2014 Zereana Jess-Huff, a 34-year-old mother, corporate ... on a platform to think outside the bra. She doesn’t ... position to raise awareness about women’s other lady parts. , ... You say the color pink and everybody knows what you’re ... fact that it has not been won when it comes ...
Breaking Medicine News(10 mins):Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3
... ... web based clinical Label Approval System - LAS a unique workflow-based label approval management ... (PRWEB) ... launch of their new web based clinical Label Approval System - LAS a unique ...
... available in <A HREF=",http://chinese.eurekalert.org/zh/emb_releases/2010-04/aaoo-amb032510.php,">Chinese . ... very thin needles are used to stimulate specific ... responses, may be an effective treatment option for ... dysfunction (PVOD), according to new research in the ...
... Despite high levels of poverty and unemployment rates that ... families in rural Oregon tend to make less use ... with Oregon State University,s Family Policy Program. OSU ... Davis of the University of Minnesota, found that the ...
... one in four elderly Americans lacked the capacity to make their ... a study of 3,746 people to be published April 1 in ... had advance directives - including living wills or durable powers of ... the time, says lead author Maria Silveira, M.D., M.P.H., physician scientist ...
... those dying needed someone else to make decisions, research finds ... advance directives, such as a living will or a durable ... type of medical care that they,ve requested as they near ... The study also found that 30 percent of people required ...
... Breast ... leading a movement to tackle the post-medical world of breast cancer, one inspiring story at ... (PRWEB) ... had breast cancer to inspire them to transform their experience into something great. Her ...
Cached Medicine News:Health News:Almac to Improve Label Approval Process in Clinical Trials 2Health News:Almac to Improve Label Approval Process in Clinical Trials 3Health News:Acupuncture may be an effective treatment for post-viral infection loss of smell 2Health News:Despite much-higher poverty rates, rural Oregonians use less public assistance 2Health News:Despite much-higher poverty rates, rural Oregonians use less public assistance 3Health News:More than one-quarter of elderly patients lack decision-making capacity at death 2Health News:More than one-quarter of elderly patients lack decision-making capacity at death 3Health News:Advance Directives Help Assure End-of-Life Wishes Are Honored 2Health News:Advance Directives Help Assure End-of-Life Wishes Are Honored 3Health News:Breast Cancer Survivor Tackles the Missing Link: Inspiring Event Offers Women Real Life Advice to Thrive After Medical Treatment Ends 2Health News:Breast Cancer Survivor Tackles the Missing Link: Inspiring Event Offers Women Real Life Advice to Thrive After Medical Treatment Ends 3Health News:Breast Cancer Survivor Tackles the Missing Link: Inspiring Event Offers Women Real Life Advice to Thrive After Medical Treatment Ends 4
The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte...
IDS Rapid Yeast Plus, a microbial identification system....
IDS Rapid NH, a microbial identification system....
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
Medicine Products: